The present invention relates to a medicine for treating a patient with advanced or recurrent cancer which is non-responsive or non-tolerant to standard chemotherapy and incurable and unresectable, the medicine comprising propagermanium.

The present invention relates to a medicine for treating a patient with advanced or recurrent cancer which is non-responsive or non-tolerant to standard chemotherapy and incurable and unresectable, the medicine comprising propagermanium.

Disclosed is a prebiotic composition comprising a combination of 2fucosyllactose (2FL) and isomaltooligosaccharide (IMO). The 2FL and IMO are present in the prebiotic composition in a weight ratio of from 1:1 to 1:10. The prebiotic composition is effective for use in methods of preventing and/or treating a gastrointestinal (GI) condition in an animal, such as irritable bowel syndrome (IBS), inflammatory bowel disease(s) (IBD), Crohn's disease, and ulcerative colitis (UC). A foodstuff or beverage, a medical food, a nutritional composition, and a kit presentation, each including the prebiotic composition, and each suitable for use in methods of reducing or suppressing inflammation in an animalian tract, are also disclosed. A method of using the prebiotic composition to prevent and/or treat a GI condition in an animal is further disclosed. The method comprises administering the prebiotic composition to the animal.

Disclosed is a prebiotic composition comprising a combination of 2fucosyllactose (2FL) and isomaltooligosaccharide (IMO). The 2FL and IMO are present in the prebiotic composition in a weight ratio of from 1:1 to 1:10. The prebiotic composition is effective for use in methods of preventing and/or treating a gastrointestinal (GI) condition in an animal, such as irritable bowel syndrome (IBS), inflammatory bowel disease(s) (IBD), Crohn's disease, and ulcerative colitis (UC). A foodstuff or beverage, a medical food, a nutritional composition, and a kit presentation, each including the prebiotic composition, and each suitable for use in methods of reducing or suppressing inflammation in an animalian tract, are also disclosed. A method of using the prebiotic composition to prevent and/or treat a GI condition in an animal is further disclosed. The method comprises administering the prebiotic composition to the animal.

The current invention relates to the use of a physiologically acceptable organic and/or inorganic vanadium compound or complex, such as for example bis(maltolato)oxovanadium (BMOV) in the prevention or amelioration of stress-induced metabolic derangement in a subject. More in particular, the invention relates to a physiologically acceptable organic and/or inorganic vanadium compound or complex for use in the amelioration of hyperglycemia in a subject suffering from stress such as elicited by a trauma, wherein the physiologically acceptable organic and/or inorganic vanadium compound or complex is administered to said subject before the trauma is inflicted to the subject. Furthermore, the invention relates to a physiologically acceptable organic and/or inorganic vanadium compound or complex for use in the prevention of hyperglycemia in a subject having a trauma, wherein the physiologically acceptable organic and/or inorganic vanadium compound or complex is administered to said subject before the subject has the trauma. In one embodiment a physiologically acceptable organic and/or inorganic vanadium compound or complex is administered to a human subject 2 to 24 hours before said human subject is subjected to surgery, for the prevention or amelioration of hyperglycemia elicited by a trauma related to the surgery. It is part of the invention that the physiologically acceptable organic and/or inorganic vanadium compound or complex are a source of vanadyl or vanadate in a patient to whom such compound or complex is administered.

A trace element solution comprises selenium, zinc, manganese and iron at a concentration of at least 60 mg/ml. The solution may further comprise at least one compound selected from the group comprising iodine, potassium iodide, sodium iodide, iron chloride, zinc oxide, manganese sulphate, sodium selenite, copper carbonate, sodium carbonate, anhydrous disodium EDTA and sodium hydroxide.

A trace element solution comprises selenium, zinc, manganese and iron at a concentration of at least 60 mg/ml. The solution may further comprise at least one compound selected from the group comprising iodine, potassium iodide, sodium iodide, iron chloride, zinc oxide, manganese sulphate, sodium selenite, copper carbonate, sodium carbonate, anhydrous disodium EDTA and sodium hydroxide.

A trace element solution comprises selenium, zinc, manganese and iron at a concentration of at least 60 mg/ml. The solution may further comprise at least one compound selected from the group comprising iodine, potassium iodide, sodium iodide, iron chloride, zinc oxide, manganese sulphate, sodium selenite, copper carbonate, sodium carbonate, anhydrous disodium EDTA and sodium hydroxide.

A fullerene-metal nanocomposite is described that comprises a metal nanoparticle bonded to a functionalized fullerene compound. A useful method of making a fullerene-metal nanocomposite is also described. The method consists essentially of the steps of mixing a solution of metal salt or metal ion with a functionalized fullerene compound, and purifying the fullerene-metal nanocomposite from the solution. Also described are antimicrobial surfaces, comprising a substrate surface and a coating on the substrate surface comprising a fullerene-metal nanocomposite that includes a metal nanoparticle bonded to a functionalized fullerene compound.

Aspects of the present disclosure relate to compounds which have enhanced oral bioavailability. A transition metal complex includes a transition metal coordinated by a macrocycle comprising the pentaaza 15-membered macrocyclic ring corresponding to Formula A and two axial ligands having the formula OC(O)X.sub.1.

##STR00001## each of the two axial ligands has the formula OC(O)X.sub.1 wherein each X.sub.1 is independently substituted or unsubstituted phenyl or C(X.sub.2)(X.sub.3)(X.sub.4); each X.sub.2 is independently substituted or unsubstituted phenyl, or substituted or unsubstituted alkyl; each X.sub.3 is independently hydrogen, hydroxyl, alkyl, amino, X.sub.5C(O)R.sub.13 where X.sub.5 is NH or O, and R.sub.13 is C.sub.1-C.sub.18 alkyl, substituted or unsubstituted aryl or C.sub.1-C.sub.18 aralkyl, or OR.sub.14, where R.sub.14 is C.sub.1-C.sub.18 alkyl, substituted or unsubstituted aryl or C.sub.1-C.sub.18 aralkyl, or together with X.sub.4 is (O); and each X.sub.4 is independently hydrogen or together with X.sub.3 is (O).